- Replimune Group Inc at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Replimune Group Inc RP1 Program Update Call TranscriptDec 05, 2023
- Replimune Group Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Replimune Group Inc to Host Virtual Investor Event TranscriptDec 07, 2022
- Replimune Group Inc To Host Investor Day TranscriptMar 30, 2022
- Replimune Group Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- Replimune Group Inc Annual Shareholders Meeting TranscriptSep 08, 2021
- Replimune Group Inc Virtual Investor Event Corporate Call TranscriptJun 03, 2021
- Replimune Group Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 11, 2021
- Replimune Group Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
- Replimune Group Inc to Provide Phase 1/2 Clinical Data Update on Patients with Melanoma and Non-Melanoma Skin Cancers - Conference Call TranscriptJun 03, 2020
- Replimune Group Inc at JPMorgan Healthcare Conference TranscriptJan 15, 2020
Replimune Group Inc at JPMorgan Healthcare Conference Transcript
Okay. Let's get started. Welcome to the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan.
I am joined by my team, Priyanka Grover and Malcolm Kuno. Our next presenting company is Replimune, and presenting on behalf of the company, we have the CEO. Philip?
Thanks, Anupam. Replimune. Replimune is the industry leader in tumor-directed oncolytic immunotherapy. We have 3 wholly owned programs, RP1, 2 and 3. RP1 data to date supports the emergence of a major skin cancer franchise.
We have 2 registrational studies ongoing. The first is in frontline cutaneous squamous cell carcinoma, where in a prior single-arm study, we showed a very impressive almost 1 in 2 complete response rate.
We have subsequently fully enrolled a 211-patient randomized controlled study of RP1 plus cemiplimab standard of care against
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)